Acute psychotic disorders treated with 5% zuclopenthixol acetate in 'Viscoleo' ('Cisordinol-Acutard'), a global assessment of the clinical effect: an open multi-centre study.
In an open clinical multi-centre trial carried out in five Danish psychiatric departments, patients suffering from acute psychosis including mania or exacerbation of chronic psychosis were given injections of 5% zuclopenthixol acetate in 'Viscoleo'. The object of the trial was to evaluate the treatment by means of a global assessment of the severity of the psychosis, the therapeutic effect and the side-effects. The results showed that the treatment was rapidly effective in reducing the severity of psychotic symptoms combined with an advantageous unspecific sedation. The side-effect profile was similar to that after other neuroleptics. Special attention should be paid, however, to a possible occurrence of acute dystonia which was observed particularly in young men with acute psychosis.
Løwert
A C
AC
Psychiatric Department, Middelfart Hospital, Denmark.
Rasmussen
E M
EM
Holm
R
R
Almbjerg
F
F
Calberg
H
H
Joensen
A
A
Nimb
M
M
Baden
H
H
Andersen
E
E
Westergård
T
T
D000208:Acute Disease; D000328:Adult; D001714:Bipolar Disorder / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003006:Clopenthixol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011618:Psychotic Disorders / Q000188:drug therapy*; D013892:Thioxanthenes / Q000627:therapeutic use*
D013892:Thioxanthenes; D003006:Clopenthixol